banner
You are not using a standards compliant browser. Because of this you may notice minor glitches in the rendering of this page. Please upgrade to a compliant browser for optimal viewing:
Firefox
Internet Explorer 7
Safari (Mac and PC)
Press Release
For brain tumors, origins matter
Thursday, November 15, 2012


Left shows medulloblastoma tumor (green) from untreated mouse. Right shows brain tissue from mouse treated with bFGF lacks tumor growth. Credit: Sanford-Burnham Medical Research Institute

Cancers arise when a normal cell acquires a mutation in a gene that regulates cellular growth or survival. But the particular cell this mutation happens in—the cell of origin—can have an enormous impact on the behavior of the tumor, and on the strategies used to treat it.

Robert Wechsler-Reya, Ph.D., professor and program director at Sanford-Burnham Medical Research Institute, and his team study medulloblastoma, the most common malignant brain cancer in children. A few years ago, they made an important discovery: medulloblastoma can originate from one of two cell types: 1) stem cells, which can make all the different cell types in the brain, or 2) neuronal progenitor cells, which can only make neurons.

Stem cells and progenitor cells are regulated by different growth factors. So, Wechsler-Reya thought, maybe the tumors arising from these cells respond differently to different therapies…

In a study published in the journal Oncogene, he and his team show that this is indeed the case. They looked at one growth factor in particular—basic fibroblast growth factor (bFGF)—and found that while it induces stem cell growth, it also inhibits neuronal progenitor cell growth.

What's more, the researchers discovered that bFGF also blocks the growth of tumors that originate from progenitors. When they administered bFGF into a mouse model of medulloblastoma, it dramatically inhibited tumor growth.

Although bFGF itself can't be used as a drug (it would cause too many off-target effects), this study suggests that molecules like it might be used to treat medulloblastoma—but only for tumors that have the appropriate origins.

"Medulloblastomas are not all alike, and the same is true for cancers of the breast, prostate and other tissues. It's critical for us to figure out how tumors differ from one another, so we can find ways to personalize cancer diagnosis and come up with treatments that are more effective and less harmful," Wechsler-Reya says.

###

Sanford-Burnham Medical Research Institute: http://www.burnham-inst.org



Thanks to Sanford-Burnham Medical Research Institute for this article.

This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.



This press release has been viewed 103 time(s).

Comments
No comments recorded.
Add Comment?
Comments are closed 2 weeks after initial post.
Friends